Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCX140-B in Primary FSGS (LUMINA-2)
NCT03703908Phase 2Terminated
- Sponsor
- Amgen
- Start
- Oct 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ilacirnon in focal segmental glomerulosclerosis (FSGS), sponsored by Amgen. Started Oct 2018; status: terminated.
02
Drugs
ilacirnon
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT03703908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03703908.